Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
enGene TherapeuticsFRA:S0N0 -2.05%19 EBIT per Share is €-1.83 as of Apr. 2026. GuruFocus rates FRA:S0N0 with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 1,169 Biotechnology companies, enGene Therapeutics ranks worse than 94.01% on this metric.
enGene Therapeutics's EBIT per Share for the
three
months ended in Apr. 2026 was €-0.36.
Its EBIT per Share for the trailing twelve months (TTM) ended in Apr. 2026 was €-1.83.
During the past 3 years, the average EBIT per Share Growth Rate was -42.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -32.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for enGene Therapeutics's EBIT per Share or its related term are showing as below:
FRA:S0N0'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -42.2 Med: -34.1 Max: -23.4
Current: -42.2
During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of enGene Therapeutics was -23.40% per year. The lowest was -42.20% per year. And the median was -34.10% per year.
FRA:S0N0's 3-Year EBIT Growth Rate is ranked worse than 94.01% of 1169
companies
in the Biotechnology industry
Industry Median: 15.4
vs FRA:S0N0: -42.20
enGene Therapeutics (FRA:S0N0) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
enGene Therapeutics EBIT per Share Related Terms
enGene Therapeutics EBIT per Share Historical Data
* Premium members only.
The historical data trend for enGene Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.83
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
enGene Therapeutics (FRA:S0N0) has a EBIT per Share of €-1.83 as of Apr. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on enGene Therapeutics and its competitors. According to the industry distribution chart, enGene Therapeutics ranks #1099 out of 1169 companies in the Biotechnology industry, placing it in the top 94%.
Is enGene Therapeutics' EBIT per Share too high?
enGene Therapeutics' current EBIT per Share is €-1.83. Based on the distribution chart, enGene Therapeutics ranks #1099 out of 1169 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, enGene Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does enGene Therapeutics' EBIT per Share compare to VTVT and GUTS?
According to the Biotechnology industry distribution chart, enGene Therapeutics ranks #1099 out of 1169 companies for EBIT per Share. This places enGene Therapeutics in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,169 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on enGene Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. enGene Therapeutics's current EBIT per Share is €-1.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is enGene Therapeutics stock overvalued right now?
enGene Therapeutics (FRA:S0N0) has a current EBIT per Share of €-1.83. The current EBIT per Share is €-1.83. enGene Therapeutics' overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For enGene Therapeutics (FRA:S0N0), the current EBIT per Share is €-1.83 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
19GF Score
Get the complete analysis for FRA:S0N0
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:S0N0 has been successfully added to your 
